Metabolic Syndrome
Conditions
Keywords
dietary supplement, cardiovascular health, oxidative stress
Brief summary
The purpose of this study is to investigate the health benefits of a recently developed multimineral/multivitamin/phytochemical (MVM/phytochemical) nutritional supplement. This newly developed supplement - an advancement of a previous formula designed to enhance human health by providing RDA-levels of essential vitamins and minerals - contains eight phytochemicals selected to address fruit and vegetable undernutrition, and chosen on the basis that: 1) published research from cell culture, animal model and, when available, human clinical work, suggests that it may benefit human health, and 2) it is considered safe for human ingestion at proposed levels of consumption.
Detailed description
This study will be an eight-week, randomized, placebo controlled, parallel arm clinical trial to compare markers of nutritional, inflammatory and oxidative status, cardiovascular and neurological health as well as microbial status in subjects consuming a novel multivitamin/multimineral/phytochemical (MVM/phytochemical) supplement compared to subjects consuming a placebo tablet. In addition, this study will evaluate whether the MVM/phytochemical supplement improves subjects sense of well-being as evaluated by a quality-of-life survey. The study will aim to enroll 112 consenting men and women characterized as having metabolic syndrome. Potential subjects will be recruited through flyers, newspapers and advertisements placed throughout the community. Consented subjects will undergo a 28-day washout, followed by a 56-day trial period. Biological samples (blood, urine, stool, saliva) will be collected at baseline (day 0) and at day 56. Diet and exercise history, as well as a quality of life survey, will be collected at these time points as well. Risk to participants is expected to be minimal and will be outlined through an informed consent.
Interventions
DIETARY_SUPPLEMENTMVM/phytochemical supplement
Consumption of an MVM/phytochemical supplement for 8 weeks
DIETARY_SUPPLEMENTPlacebo
Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
Sponsors
KGK Science Inc.
USANA Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Body Mass Index of 29.9 to 40 kg/m2 ±1 kg/m2 * Waist measurement for males ≥ 102 cm (40 inches) or for females ≥ 89 cm (35 inches) * two or more of the following risk factors: * Elevated blood pressure ( 130/85 mm Hg) * Fasting elevated triglycerides \> 1.69 mmol/L ( 150 mg/dL) * Elevated fasting glucose \> 5.56 mmol/L ( 100 mg/dL) and \<7.0 mmol/L (\<126 mg/dL) * Low HDL cholesterol \<1.29 mmol/L ( 50 mg/dL) for females, and \<1.03 mmol/L ( 40 mg/dL) for males * Not currently taking a multivitamin/mineral, antioxidant supplement, or other dietary supplements or are willing to wash out for 4 weeks before enrollment
Exclusion criteria
* Pregnant and/ or lactating females or females trying to become pregnant * Use of lipid lowering medications * Lipid lowering OTC or herbal supplements within 3 weeks of enrollment * Use of conventional multivitamin/mineral, antioxidant supplements or other dietary supplements within four weeks prior to enrollment * Insulin-dependent Type I and Type II diabetics * Diabetic men \> 45 years and diabetic women \> 55 years * Metformin or other diabetes medications are prohibited in this study * Type II diabetes controlled by diet and/or exercise * Elevated blood pressure ( 160/95 mm Hg) at screening * Individuals with a history of coronary artery disease, previous myocardial infarction, peripheral vascular disease, or atherosclerosis * Men above 50 years and women above 60 years who have a 10-year risk of cardiovascular event FRS between 10% and 19% (inclusive) at screening and who present with one of the following LDL-C \> 3.5 mmol/L, TC/HDL-C ratio \> 5.0, or hs-CRP \> 2 mg/L * Individuals with a 10-year risk of cardiovascular event FRS \< 10% at screening and present with LDL-C \> 5.0 mmol/L or TC/HDL-C ratio \> 6.0 * Participants taking blood thinners * Participants with stomach ulcers, gall stones, or bile duct obstruction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HDL Cholesterol | 8 weeks | Effect of MVM/Phytochemical Supplement on HDL-cholesterol levels compared to placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oxidative Stress | 8 weeks | change in oxidative stress markers between MVM/Phytochemical Supplement and placebo including antioxidant enzyme activity (SOD, Catalase, GSH-Px) and markers of oxidative stress (GSH/GSSG, 8-isoprostanes) |
| Cardiovascular Health | 8 weeks | change in markers of cardiovascular health between MVM/Phytochemical including Cholesterol levels Supplement and placebo (LDL, HDL, total cholesterol, homocysteine) |
| Nutritional status | 8 weeks | change in markers of nutritional status between MVM/Phytochemical Supplement and placebo including vitamins A,D,E,K,C,B6,B12 and folate) |
| Inflammation | 8 weeks | change in inflammatory markers between MVM/Phytochemical Supplement and placebo including circulating levels of IL-1b, TNF-a, and IFNg |
| Microbiome | 8 weeks | change in microbiome between MVM/Phytochemical Supplement and placebo using 16s analysis |
| Quality of Life | 8 weeks | difference in self-perceived quality of life between MVM/Phytochemical Supplement and placebo using the SF-36 questionnaire |
| Neurological Health | 8 weeks | change in markers of neurological health between MVM/Phytochemical Supplement and placebo |
Countries
Canada
Outcome results
None listed